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CONTEXT AND OBJECTIVE: Adverse drug reac-
tions are a signifi cant problem in patients on 
antiretroviral therapy (ART). We determined liver 
enzyme elevation frequencies in HIV-infected 
children and adolescents receiving ART, and 
their association with risk factors.
DESIGN AND SETTING: Cross-sectional study, 
at the Pediatrics Immunodefi ciency Division, 
University Hospital, Universidade Estadual de 
Campinas. 
METHODS: Medical records of 152 children and 
adolescents (54.6% male; median age 7.48 years) 
were analyzed, with a mean of 2.6 liver enzyme 
determinations per patient. Clinically, patients 
were classifi ed in categories N (6), A (29), B 
(78) and C (39). Serum levels of aspartate ami-
notransferase and alanine aminotransferase were 
evaluated. Hepatotoxicity was scored as grade 
1 (1.1-4.9 times upper limit of normality, ULN), 
grade 2 (5.0-9.9 times ULN), grade 3 (10.0-15.0 
times ULN) and grade 4 (> 15.0 times ULN). To 
assess hepatotoxicity risk factors, odds ratios (OR) 
and adjusted odds ratios (aOR) for age, gender, 
TCD4+ cell count, viral load and medication usage 
were calculated.
RESULTS: We observed grade 1 hepatotoxicity 
in 19.7 % (30/152) patients. No cases of grade 
2, 3 or 4 were detected. There was a signifi cant 
association between hepatotoxicity and use of 
sulfonamides (OR, 3.61; 95% confi dence interval 
(CI), 1.50–8.70; aOR, 3.58; 95% CI, 1.44–8.85) 
and antituberculous agents (OR, 9.23; 95% CI, 
1.60–53.08; aOR, 9.05; 95% CI, 1.48–55.25). 
No toxicity was associated with ART. 
CONCLUSIONS: One fi fth of patients experienced 
mild hepatotoxicity, attributed to antituberculous 
agents and sulfonamides. Our results suggest that 
ART was well tolerated. 
KEY WORDS: Aids. Pediatrics. Highly active 
antiretroviral therapy. Drug toxicity. Anti-bacte-
rial agents.
INTRODUCTION
Antiretroviral therapy (ART) has had an 
effect on the lives of HIV-infected children and 
adults. Survival has improved, patients have re-
quired fewer hospitalizations, and the incidence 
of opportunistic infections has decreased.1 
However, hepatotoxicity is a signifi cant prob-
lem in patients on highly active antiretroviral 
therapy (HAART). In approximately 6% to 
30% of treated patients, ART is associated 
with signifi cantly increased serum liver enzyme 
levels, which may require discontinuation of 
treatment.2,3 In adults starting on ART, 14-
20% will experience elevations of liver enzyme 
levels4,5 and 2-10% will need to stop receiving 
ART due to severe liver injury.6 
Differential diagnoses for liver diseases in 
patients with HIV infection are often a dif-
fi cult task. Abnormal levels of liver enzymes 
are common and may be caused by HIV 
itself, hepatitis viruses, systemic opportunis-
tic infections, malignancies or drug-induced 
hepatotoxicity.6 
The mechanisms involved in HAART-
derived liver toxicity are poorly understood. 
Elevations in serum liver enzyme levels have 
been described in relation to all the major 
classes of antiretrovirals. The underlying 
mechanisms proposed have included mito-
chondrial toxicity relating to several nucle-
oside analog reverse transcriptase inhibitors 
(NRTIs) and hypersensitivity reactions relat-
ing to non-nucleoside reverse transcriptase 
inhibitors (NNRTIs).7
It has been estimated that 2.5 million 
children worldwide are living with acquired 
immunodeficiency syndrome (AIDS), ac-
cording to data collected for the 2004 report 
from the UNAIDS/WHO Working Group on 
Global HIV/AIDS.8 In Brazil, 10,917 cases of 
AIDS were reported in children under 13 years 
of age from 1983 to 2004.9
Brazil was the fi rst developing country to 
implement a large-scale universal antiretroviral 
distribution program. Approximately 141,000 
patients are receiving free antiretroviral drugs 
through the public health system.10 However, 
most information relating to therapeutic toxic-
ity comes from the settings of developed coun-
tries. There are few data on liver toxicity among 
the pediatric population receiving antiretroviral 
treatment in developing countries.
OBJECTIVE
The aim of this study was to determine 
the frequencies of asymptomatic or sympto-
matic liver enzyme elevations in HIV-positive 
children and adolescents receiving ART in 
outpatient settings and to correlate these 
frequencies with risk factors.
MATERIAL AND METHODS
This was a cross-sectional study that in-
cluded all 152 HIV-infected children and ado-
lescents who were followed up at the Pediatrics 
Immunodefi ciency Division of the University 
Hospital, Universidade Estadual de Campinas, 
State of São Paulo, Brazil, from March 2003 to 
April 2004. These patients were receiving ART 
and had undergone measurements of serum 
aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT). They were treated by 
specialized staff, in accordance with the guide-
lines established by the Brazilian Ministry of 
Health.11 The medical school’s Ethics Review 
Board approved the study.
Data were collected from the patients’ 
records, including clinical and immunological 
categories, HIV viral load, antiretroviral drug 
use, antimicrobial therapy (antituberculous 
agents, sulfonamides, imidazoles and mac-
rolides) and serum levels of AST and ALT.
Clinically, they were classifi ed accord-
ing to the 1994 criteria of the Centers for 
Disease Control and Prevention (CDC)12 as 
asymptomatic (category N), mildly symp-
tomatic (category A), moderately sympto-
matic (category B) or severely symptomatic 
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(category C). Their immunological status was 
defi ned as class 1 (no immunosuppression), 2 
(moderate immunosuppression) or 3 (severe 
immunosuppression) on the basis of the 
TCD4+ cell count adjusted for age.
For the purpose of this report, we pre-
sumed that the antiretroviral drugs prescribed 
were taken; antiretroviral drug use was in-
cluded in the analysis unless there was docu-
mentation that they were not taken.
Monitoring of hepatotoxicity
During the year of reviewing the medi-
cal fi les, we collected data from laboratory 
tests on liver function and from abdominal 
ultrasonography. Imaging studies were per-
formed only on patients with hepatomegaly 
and clinical suspicion of liver disease. The 
median number of repeated liver enzyme 
determinations was 2.6 (range: 1-5) per 
patient. Only the highest value of ALT and 
AST was considered. 
ALT and AST levels were determined 
by using Refl otron® Plus at 37° C (Roche 
Diagnostics, Mannheim, Germany). Titers 
were expressed in U/l.
The medical records were reviewed 
to exclude other potential causes of liver 
disease, such as Epstein-Barr virus (EBV), 
cytomegalovirus (CMV) and hepatitis A, B 
and C. Liver biopsy was performed on only 
one patient.
Hepatic toxic effects were graded accord-
ing to the toxicity tables of the AIDS Divi-
sion of the Pediatrics AIDS Clinical Trials 
Group.13 Hepatotoxicity was considered to 
be present when ALT and AST levels rose 
above the upper limits of normality (ULN). 
Normality was considered to be the values 
defi ned by Fischbach and Zawta in 1992.14 
The scoring system was the following: grade 1 
(1.1 - 4.9 x ULN), grade 2 (5.0 - 9.9 x ULN), 
grade 3 (10.0 - 15.0 x ULN) and grade 
4 (> 15.0 x ULN). 
In the group presenting hepatotoxicity, 
the clinical data and ALT and AST levels were 
reviewed from the beginning of the clinical 
follow-up at our service, in order to rule out 
previous liver disease.
Peripheral T lymphocytes and their sub-
populations were quantifi ed by fl ow cytometry 
in FACS Count® equipment (Beckton-Dickin-
son, Franklin Lakes, NJ, USA). The results were 
expressed as the total number of cells/mm3.
The NucliSens® assay (Organon-Teknika, 
Durham, NC, USA) was used to determine 
quantitative plasma HIV-1 RNA levels, with 
a lower limit of quantifi cation of 80 RNA 
copies/ml. The assays were performed in the 
certifi ed AIDS laboratory at our institution, 
in accordance with the standards recom-
mended by the Brazilian Health Ministry.15
Data analysis
All data collected were organized into 
a database using Excel software (Micro-
soft® 2000, Microsoft, Redmond, USA). 
The statistical analysis was performed 
by means of the Statistical Package for 
the Social Sciences (SPSS) software, ver-
sion 11.0 (SPSS, Chicago, USA). Asso-
ciations between dependent and independent 
variables were initially assessed using univari-
ate analysis. Odds ratios (OR) were calculated, 
and the chi-squared or Fisher exact test was 
used. Variables that showed signifi cant as-
sociations with hepatotoxicity risk were then 
assessed by multivariate analysis, with adjusted 
odds ratios (aOR), using unconditional lo-
gistic regression and the forward stepwise 
method, and probability levels of 0.05 and 
0.10, respectively. We investigated associations 
between the occurrence of liver abnormalities 
in laboratory tests and the clinical variables 
evaluated. The variables included in the 
basic model were age, gender, immunologi-
cal category, last viral load and antimicrobial 
therapy. The use of antituberculous agents, 
sulfonamides, imidazoles and macrolides was 
analyzed separately. We also did analysis on 
the commonly coprescribed antiretrovirals (zi-
dovudine, lamivudine, didanosine, stavudine, 
efavirenz, nevirapine, nelfi navir, ritonavir and 
lopinavir), to improve the power of the logistic 
model to separate associations.
RESULTS
Among the 152 children and adolescents 
receiving ART, 54.6% were boys. Their ages 
ranged from 0.6 to 18.2 years (median: 7.48). 
The mean TCD4+ lymphocyte count was 
690.8 cells/mm3. The data on the patients’ 
characteristics collected cross-sectionally are 
displayed in Table 1.
While 148 children had been infected 
with HIV vertically, four had been infected 
through blood transfusion. Using the CDC 
guidelines12 the clinical classifi cation of the 
pediatric HIV infection was that there were 
six patients in category N, 29 in A, 78 in B 
and 39 in C.
Thirty patients (19.7%) had elevations 
in transaminase levels: 20 of them in AST 
and 14 in ALT. The hepatotoxicity score 
was limited to grade 1. Overall, the mean 
ALT level was 22 U/l (standard deviation, 
SD = 21.1 U/l) and the mean AST level was 
36.5 U/l (SD = 19.7 U/l). These results are 
summarized in Figure 1.
Twelve out of the 30 patients presenting 
liver enzyme abnormalities underwent ab-
dominal ultrasonography. Among these, seven 
(58.3%) had a diagnosis of hepatosplenom-
egaly with hepatic steatosis. Abdominal pain 
was reported in three patients.
One patient had hepatitis C and another 
patient had histoplasmosis, which probably 
were the causes of their transient elevation of 
transaminase levels. 
With regard to ART, the 152 study sub-
jects were receiving combinations of nucle-
Table 1. Hepatotoxicity in HIV-infected children and adolescents on antiretroviral 
therapy, in relation to gender, viral load and classifi cation. Data were collected from 
March 2003 to April 2004 in a university hospital
Hepatotoxicity
Yes No OR (95% CI)
Gender
    Male 13 69 1.70 (0.76-3.81)
    Female 17 53
Viral load (copies/ml)
    > 100,000 3 2 6.66 (1.06-41.85)
    < 100,000 27 120
Immunological category
    1 5 19 1.00
    2 8 61 0.49 (0.14-1.70)
    3 17 42 1.53 (0.49-4.78)
Clinical category
    N + A 5 30 1.00
    B 13 65 1.19 (0.39-3.67)
    C 12 27 2.66 (0.83-8.54)
OR = odds ratio; CI = confi dence interval; N = asymptomatic; A = mildly symptomatic; B = moderately symptomatic; 
C = severely symptomatic.
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oside analogue reverse transcriptase inhibitors 
(NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) or protease inhibitors, in 
accordance with national guidelines11 (Table 
2). Assessment of the antiretroviral regimens 
indicated that 15.8% of the patients (24/152) 
were on double therapy, 75.7% (115/152) on 
triple therapy and 8.6% (13/152) were on 
four-drug regimens.
In addition, 35 patients were on prophylaxis 
or therapy for opportunistic infections. Among 
these, 27 received trimethoprim/sulfamethoxa-
zole (TMP-SMX), eight azithromycine, two 
ketoconazole, three fl uconazole, six isoniazid, 
three rifampicin, two ethambutol, four sulfadi-
azine and pyrimethamine (Table 3). 
The multiple logistic regression model 
revealed that hepatotoxicity was associ-
ated only with the use of sulfonamides 
(aOR: 3.58; 95% confidence interval, 
CI: 1.44 – 8.85) and antituberculous agents 
(aOR: 9.05; 95% CI: 1.48 – 55.25) 
(Table 3). Coadministration of antitubercu-
lous agents for four patients out of the 30 pre-
senting hepatotoxicity (13.3%), consisting 
of an association of isoniazid and rifampicin 
(two cases) or isoniazid alone as a prophylac-
tic (two cases), could have contributed to the 
transitory increase in liver enzymes. 
DISCUSSION
Mild liver toxicity was observed in 
19.7% of the HIV-infected children and 
adolescents on ART. This result suggests 
that this population tolerated ART well, 
probably because of an absence of risk 
factors that would contribute towards the 
development of severe liver injury in adults 
such as hepatitis C virus and/or hepatitis B 
virus coinfection, older age, high alcohol 
intake and use of illicit drugs.2,16
Grade 1 hepatotoxicity, as assessed by AST 
levels, was found in three patients (8%) out of 
a group of 36 HIV-1 infected children who 
were treated with four or fi ve antiretroviral 
agents.17 Another recent study18 showed that 
16% of 43 children on ART developed hepa-
totoxicity with elevated liver enzyme levels at 
least fi ve times the baselines values. 
Hepatotoxicity ranges in severity from the 
absence of symptoms to liver insuffi ciency, and 
the outcomes range from spontaneous reso-
lution to liver failure and death. Low-grade 
hepatotoxicity is a warning for physicians 
caring for patients on ART.16
Liver enzyme elevations are common 
in HIV-infected patients, especially those 
treated with HAART. Despite such reports, 
analysis of the events surrounding liver 
Figure 1. Box-plot showing distribution of aspartate aminotransferase (AST) and ala-
nine aminotransferase (ALT) serum levels according to hepatotoxicity categories in 




































Table 2. Hepatotoxicity in HIV-infected children and adolescents followed up in a 
university hospital, in relation to antiretroviral therapy
Drug
Hepatotoxicity
Yes No OR (95% CI)
Stavudine
    Yes 10 25 1.93 (0.80-4.66)
    No 20 97
Lamivudine
    Yes 12 56 0.78 (0.34-1.77)
    No 18 66
Zidovudine
    Yes 20 97 0.51 (0.21-1.23)
    No 10 25
Didanosine
    Yes 18 66 1.27 (0.56-2.86)
    No 12 56
Nevirapine
    Yes 1 1 4,17 (0.25-68.69)
    No 29 121
Efavirenz
    Yes 5 12 1,83 (0.59-5.67)
    No 25 110
Lopinavir/ritonavir
    Yes 4 7 2.52 (0.68-9.27)
    No 26 115
Ritonavir
    Yes 4 18 0.88 (0.27-2.85)
    No 26 104
Nelfi navir
    Yes 17 71 0.93 (0.41-2.10)
    No 13 51
OR = odds ratio; CI = confi dence interval.
n = number of patients; ° outliers; ∗ extremes.
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Table 3. Multiple logistic regression for hepatotoxicity risk factors in HIV-positive children 
and adolescents followed up in a university hospital
Hepatotoxicity
Yes No OR (95% CI) aOR (95% CI)
Viral load (copies/ml)
    > 100,000 3 2 6.66 (1.06-41.85) 1.78 (0.22-14.11)
    < 100,000 27 120
Drugs
Antituberculous
    Yes 4 2 9.23 (1.60-53.08) 9.05 (1.48-55.25)
    No 26 120
Sulfonamides
    Yes 12 9 3.61 (1.50-8.70) 3.58 (1.44-8.85)
    No 18 103
Antifungal azoles
    Yes 1 4 1.01 (0.10-9.44) ND
    No 29 118
Macrolides
    Yes 2 7 1.17 (0.23-5.95) ND
    No 28 115
OR = odds ratio; CI = confi dence interval; aOR = adjusted odds ratio; ND = not done (non-signifi cant odds ratio).
enzyme elevations is limited, because HIV-
infected patients present several risk factors 
for biochemical abnormalities, and a precise 
etiology is rarely defi ned clearly.19
Other than HAART-derived hepatotox-
icity, some liver diseases are often associated 
with HIV infection and should also be ruled 
out.19 Our results showed no significant 
relationship between grade 1 hepatotoxicity 
and higher viral load (≥ 100,000 copies/ml), 
while coexistence with hepatitis C or histo-
plasmosis infection was documented in two 
isolated patients.
Use of sulfonamides and coadministration 
of antituberculous agents were signifi cantly 
associated with grade 1 hepatotoxicity. Differ-
ently to an earlier report,18 the hepatotoxicity 
observed in our study was not related to ART 
or to clinically and immunologically compro-
mised conditions.
HAART is a combination therapy of 
several antiretroviral drugs and thus can cause 
hepatotoxic drug interactions by itself. In 
particular, NNRTIs and protease inhibitors 
interact with cytochrome P450 and thus 
mutually alter their serum half-lives.19 A com-
bination regimen of ritonavir, zidovudine, and 
lamivudine was found to be generally safe and 
produced sustained viral suppression in more 
than one third of infants who started therapy 
before two years of age.20
The fi nding that 15.8% of our patients 
continued to receive dual-ART in 2004 
can probably be attributed to the fact that 
these patients continued to have low viral 
loads and adequate immune function. In ac-
cordance with the guidelines for prescribing 
three antiretroviral drugs initially, preferably 
including a protease inhibitor or an NNRTI, 
most children in this study were receiving triple 
therapy. The survival rates have increased in 
association with triple antiretroviral use.21 As 
children and adolescents on ART go through 
hormonal changes and growth spurts associated 
with puberty, the late complications and toxic-
ity of chronic exposure to HAART also need to 
be carefully monitored and evaluated.
Many common antibiotics, antifungals 
and antivirals prescribed for HIV-infected 
patients are independently associated with 
hepatotoxicity. Drugs commonly used for 
HIV-infected patients can induce cholestatic 
(TMP-SMX) or hepatocellular (isoniazid) 
patterns.16
In addition to predisposing towards 
tuberculosis, AIDS may predispose towards 
the development of drug-induced hepatotox-
icity secondary to the use of antituberculous 
agents.22 One analysis indicated a fourfold 
increased risk of drug-associated hepatitis 
in patients treated simultaneously for HIV 
and tuberculosis.23 Treatment of tuberculosis 
constitutes a particularly diffi cult problem 
among patients on HAART, because tuber-
culostatic drugs themselves carry a consider-
able risk of inducing toxic liver damage.24 A 
meta-analysis25 has shown that rifampicin 
and isoniazid, when coadministered, might 
lead to synergistic hepatotoxicity. The mean 
incidences of drug-related toxic hepatitis 
were found to be 1.6% (isoniazid), 1.1% (ri-
fampicin) and 2.6% (isoniazid + rifampicin). 
In our study, as in others,16,22,23,24 the hepato-
toxicity was mainly related to isoniazid alone 
or in association with rifampicin.
We have described clinical and laboratory 
disorders associated with a wide variety of treat-
ment combinations. In this study, patients were 
not randomly allocated to treatment. Allocation 
of treatment could have been biased, since pa-
tients with more advanced disease could have 
been given three classes of antiretrovirals. 
A longer-term study might give a more 
precise understanding of the cumulative toxic 
effects. However, such a study would also be 
more complex in view of the treatment modi-
fi cations and intercurrent illnesses expected 
during an extended follow-up.
CONCLUSION
In conclusion, one fi fth of all HIV-infected 
children and adolescents in this study had 
a high concentration of transaminases, 
characterized by hepatotoxicity grade 1. In 
addition, the risk factors for hepatotoxicity 
associated with such patients were concurrent 
use of sulfonamides and coadministration of 
antituberculous agents. 
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RESUMO
Hepatotoxidade em crianças e adolescentes infectados pelo HIV em terapia antiretroviral 
CONTEXTO E OBJETIVO: Reações adversas a drogas são um problema signifi cativo em pacientes sob terapia 
antiretroviral (TARV). Determinamos a freqüência de valores elevados de enzimas hepáticas em um grupo 
de crianças e adolescentes infectados pelo HIV sob TARV e os fatores de risco associados.
TIPO DE ESTUDO E LOCAL: Estudo transversal, realizado na Divisão de Imunodefi ciência em Pediatria, 
Hospital das Clínicas, Universidade Estadual de Campinas.
MÉTODOS: Foram analisados prontuários médicos de 152 crianças e adolescentes (54,6% masculino) 
infectados pelo HIV sob TARV, com dosagens de enzimas hepáticas, em média, 2,6 exames por pa-
ciente. A mediana de idade foi 7,48 anos. Clinicamente os pacientes foram classifi cados nas categorias 
N (6), A (29), B (78) e C (39). Foram avaliados os níveis séricos de aspartato aminotransferase e alanina 
aminotransferase. O sistema de escore da hepatotoxicidade foi: grau 1 (1,1 a 4,9 x• limite superior ao 
normal, i.e., LSN), grau 2 (5,0 – 9,9 x LSN), grau 3 (10,0 – 15,0 x •LSN) e grau 4 (>15,0 x •LSN). Para 
determinar os fatores de risco de hepatotoxicidade, foram avaliados odds ratio (OR) e odds ratio ajustado 
(aOR) para idade, gênero, contagem de linfócitos TCD4+ e uso de medicações.
RESULTADOS: Observamos hepatotoxicidade grau 1 em 19,7% (30/152) pacientes. Não foi detectada 
hepatotoxicidade grau 2, 3 ou 4. Houve uma associação signifi cativa entre a hepatotoxicidade e uso de 
sulfas (OR, 3,61; IC 95%, 1,50 –8,70; ORajustado, 3,58; IC 95%, 1,44 – 8,85) e agentes antituberculose 
(OR, 9,23; IC 95%, 1,60 – 53,08; ORajustado, 9,05, IC 95%, 1,48 – 55,25), mas não estava associada 
com TARV.
CONCLUSÃO: Um quinto dos pacientes apresentaram hepatotoxicidade leve, atribuída ao uso de agentes 
antituberculose e sulfas. Nossos resultados sugerem que TARV foi bem tolerada. 
PALAVRAS-CHAVE: AIDS. Pediatria. Terapia anti-retroviral de alta atividade. Toxicidade de drogas. Agentes 
antibacterianos.
